I must admit that fully funding what (at present) amounts pretty much to a research division, makes our bottom line look less attractive than it could be. Pictures of the professor on some ski slope don't do much for me -- but addressing a conference to announce a cure for herpes would. If the company was only focused on further developing the hospital infusion equipment side and fast tracking uses for our world leading ADAPT technology, then I think that our rapid growth would be almost a certainty and I would be assured of finally getting my investment back.
Overall; I feel that retaining the vax side of this company is a bit like gripping a wolf by the ears ....... don't want to hold it but don't dare to let go.
AHZ Price at posting:
34.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)